Becton Dickinson
About: Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
Employees: 74,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
278% more call options, than puts
Call options by funds: $792M | Put options by funds: $209M
25% more funds holding in top 10
Funds holding in top 10: 20 [Q4 2024] → 25 (+5) [Q1 2025]
2% more first-time investments, than exits
New positions opened: 134 | Existing positions closed: 131
2% less repeat investments, than reductions
Existing positions increased: 593 | Existing positions reduced: 606
3% less capital invested
Capital invested by funds: $60.5B [Q4 2024] → $58.4B (-$2.05B) [Q1 2025]
1.07% less ownership
Funds ownership: 89.86% [Q4 2024] → 88.79% (-1.07%) [Q1 2025]
2% less funds holding
Funds holding: 1,597 [Q4 2024] → 1,572 (-25) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$185
7%
upside
Avg. target
$215
25%
upside
High target
$261
52%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
Barclays Matt Miksic | 40%upside $241 | Overweight Maintained | 3 Jun 2025 |
Citigroup Joanna Wiensch | 7%upside $185 | Neutral Downgraded | 22 May 2025 |
Morgan Stanley Patrick Wood | 14%upside $196 | Overweight Maintained | 6 May 2025 |
Piper Sandler Jason Bednar | 7%upside $185 | Neutral Downgraded | 2 May 2025 |
Stifel Rick Wise | 30%upside $224 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 11 articles about BDX published over the past 30 days
Neutral
Seeking Alpha
5 days ago
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.
Positive
Seeking Alpha
5 days ago
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.
Positive
Seeking Alpha
1 week ago
June's Top Dividend Aristocrat Fat Pitches: Blue-Chip Bargains You Can't Miss
Despite bubble fears, 91% of market gains since 2009 are justified by fundamentals like earnings, dividends, and strong balance sheets. Stocks appear overvalued at face value, but strong long-term earnings growth potential could justify current prices. These five dividend aristocrats, currently trading at a 42% historical discount, offer exceptional return potential and a significant margin of safety.
Positive
Seeking Alpha
1 week ago
June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, and Canadian Utilities—meet the ideal 'dogcatcher' standard for fair pricing and dividend safety. Analyst projections suggest select Dividend Kings could deliver up to 58% total returns by June 2026, with lower volatility than the market overall.
Negative
Zacks Investment Research
2 weeks ago
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Neutral
PRNewsWire
2 weeks ago
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J. , May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).
Positive
Seeking Alpha
2 weeks ago
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.
Neutral
PRNewsWire
2 weeks ago
BD to Present at Goldman Sachs 46th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J. , May 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 2:00 pm Eastern Time.
Neutral
PRNewsWire
3 weeks ago
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'
FRANKLIN LAKES, N.J. , May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology 1 and Cancer Medicine 2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients.
Positive
Zacks Investment Research
3 weeks ago
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Charts implemented using Lightweight Charts™